About Monal Therapeutics:

There are few targeted, non-toxic ways to kill cancer.

Most tools available to clinicians, such as surgery, chemotherapy, radiation, and immunotherapies, come with significant toxicity, and side-effects.

These treatments use poisons,  trying to kill more cancerous cells then healthy ones. They hope to kill the cancer without killing the patient. Regardless of whether they are successul significant side-effects occur.

Patients Deserve Better...

Monal is:

  • Able to target dysregulated Mitochondria and attack cancer's heart within the cell
  • Non-toxic in all in-vivo and in-vitro testing
  • A patented platform with multiple indications in final pre-clinical studies
  • A biotech company with a robust pipeline and significant partnership opportunities

Monal’s platform uses nano-encapsulation to deliver compounds intracellularly, directly targeting mitochondria in cancer cells.

Monal has achieved significant POC, target affinity, and high degrees of potency via in-vitro and in-vivo studies (mice, rats, dogs) for the treatment of cancers, including: breast, glioma, melanoma, colon, ovarian, prostate and pancreatic cancers.

Monal’s targets Mitochondria which are essential for cell function and are dysregulated in cancers, contributing to metastasis, drug resistance, and cancer stem cell survival. By focusing on mitochondrial dynamics, Monal’s platform acts to normalize these functions, leading to the death of cancer cells and sparing healthy ones.